Qiagen (NYSE:QGEN) Stock Rating Upgraded by Wolfe Research

Qiagen (NYSE:QGEN) was upgraded by equities research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm presently has a $50.00 target price on the stock. Wolfe Research’s price objective would suggest a potential upside of 21.73% from the stock’s previous close.

Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, June 18th. Stifel Nicolaus lowered their price target on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.05.

Qiagen Price Performance

NYSE QGEN opened at $41.08 on Thursday. The stock has a market capitalization of $9.37 billion, a P/E ratio of 27.54, a P/E/G ratio of 3.15 and a beta of 0.42. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.70. The business’s fifty day moving average is $43.23 and its two-hundred day moving average is $43.57. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. During the same quarter in the prior year, the company earned $0.53 earnings per share. The firm’s revenue was down 5.4% on a year-over-year basis. On average, research analysts forecast that Qiagen will post 2.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Qiagen

Large investors have recently bought and sold shares of the business. Riverview Trust Co bought a new stake in Qiagen in the first quarter worth $28,000. Tower Research Capital LLC TRC boosted its holdings in Qiagen by 66.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock valued at $31,000 after acquiring an additional 283 shares during the period. Park Place Capital Corp bought a new stake in Qiagen during the first quarter valued at about $36,000. Quarry LP bought a new stake in Qiagen during the fourth quarter valued at about $38,000. Finally, Toronto Dominion Bank bought a new stake in Qiagen during the third quarter valued at about $41,000. 70.00% of the stock is currently owned by institutional investors.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.